dc.contributor | Departament de Salut |
dc.contributor.author | Programa d'Harmonització Farmacoterapèutica |
dc.date.accessioned | 2022-03-04T11:10:53Z |
dc.date.available | 2022-03-04T11:10:53Z |
dc.date.issued | 2022 |
dc.identifier.citation | Programa d'Harmonització Farmacoterapèutica. Tractament de la psoriasi en plaques: informe d'avaluació de resultats. Barcelona: Servei Català de la Salut; 2022. |
dc.identifier.uri | https://hdl.handle.net/11351/7116 |
dc.description | Psoriasis; Biological treatments; Apremilast |
dc.description.abstract | This report selected the data of patients with moderate to severe plaque psoriasis treated with adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, tildrakizumab, risankizumab, secukinumab and ustekinumab public use of Catalonia (SISCAT) and that they were included in the CatSalut register of patients and treatments (RPT) from 2015. In this period, 6,800 treatments have been used to treat 4,860 patients diagnosed with plaque psoriasis. , who had an average age of 50 years and of whom 58% were men. The initial criteria set out in the Agreement have been met in 4,775 (70.2%) treatments (1st line [52%] and 2nd line and subsequent [91%]). The response rate for first-line treatments was 80.7% and for second-line treatments 77.5%. Overall, the response rate for biologic drugs was 80%, while that of aprililast was 10% lower. |
dc.language.iso | cat |
dc.publisher | Servei Català de la Salut |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Psoriasi - Tractament |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Psoriasis |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Drug Evaluation |
dc.title | Tractament de la psoriasi en plaques: informe d'avaluació de resultats |
dc.type | info:eu-repo/semantics/report |
dc.subject.decs | psoriasis |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | evaluación de medicamentos |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |